MedTrace Logo

Study to Investigate the Safety and Efficacy of BRII-835 and BRII-179 Combination Therapy Treating Chronic Hepatitis B Virus (HBV) Infection

NCT04749368 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 91

Last updated 2024-06-18

No results posted yet for this study

Summary

This is an open label, randomized, parallel-group study to evaluate the safety and efficacy of combination treatment BRII-835 (VIR-2218) and BRII-179 (VBI-2601) in adult participants with chronic HBV infection

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

BRII-835 (VIR-2218)

BRII-835 (VIR-2218) will be given by subcutaneous injection

BIOLOGICAL

BRII-179 (VBI-2601) with IFN-α

BRII-179 (VBI-2601) with IFN-α will be co-administered by intramuscular injection

BIOLOGICAL

BRII-179 (VBI-2601)

BRII-179 (VBI-2601) will be administered by intramuscular injection

Sponsors & Collaborators

  • Vir Biotechnology, Inc.

    collaborator INDUSTRY

  • VBI Vaccines Inc.

    collaborator INDUSTRY

  • Brii Biosciences Limited

    lead INDUSTRY

Principal Investigators

  • Xiaofei Chen · Brii Biosciences Limited

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-12
Primary Completion
2023-07-04
Completion
2023-07-04
FDA Drug
Yes

Countries

  • Australia
  • China
  • New Zealand
  • Singapore
  • South Korea
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04749368 on ClinicalTrials.gov